In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment right until disease progression or the participants are unable to tolerate the study drugs. Ubiquitin-associated proteins that control The soundness of crucial super enhancer-mediated proteins have also https://isabbv-744effectiveforhem68912.theblogfairy.com/31409673/5-easy-facts-about-is-abbv-744-effective-for-hematologic-cancers-described